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applied from Finnish medicine tariff. RESULTS: All the patients
with baseline LDL-C level of 4,0 mmol/l (SD = 0,25 mmol/l)
reached PTT when using rosuvastatin 10 mg, 20 mg or 40 mg.
Corresponding numbers for simvastatin 20 mg, 40 mg and
80 mg were 4%, 57%, and 99%, respectively. The incremental
annual cost of rosuvastatin 10 mg compared to generic simv-
astatin 40 mg was 710€ per additional PTT. When patient’s
baseline LDL-C level exceeded 4.2 mmol/l rosuvastatin pro-
duced the lowest annual medicine costs per PTT. With lower
levels of LDL-C simvastatin was the most cost-effective to use.
Atorvastatin was less effective and more costly than rosuvasta-
tin with all baseline LDL-levels and was therefore dominated.
CONCLUSION: The cost-effectiveness of statins depends on
patient’s cardiovascular risk proﬁle and baseline cholesterol
level. In Finland rosuvastatin is cost-effective in reaching Euro-
pean LDL-C target of 2.5 mmol/l when patient’s LDL-C level
exceeds 4.2 mmol/l.
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OBJECTIVES: Hypertension is an independent risk factor for
cardiovascular disease, which results in an enormous burden to
society, both in terms of health and costing. Therefore, health
gains and related cost-savings could be achieved by optimizing
antihypertensive treatment. The aim of this study was to esti-
mate the cost-effectiveness of treating patients with hyperten-
sion in The Netherlands with angiotensin II receptor blockers
(ARBs). METHODS: Our analysis comprised: 1) estimation of
the cost-effectiveness based on a published, prospective, ran-
domized, double-blind clinical trial comparing blood pressure
lowering of olmesartan, losartan, valsartan and irbesartan;
blood pressures at 8 weeks were inserted in the Framingham
risk functions to estimate cardiovascular complications,
using an international health economic model, and 2) a cost-
minimization analysis (assuming comparable effectiveness)
using daily practice prescription data from IADB.nl (50 phar-
macies), a database covering a population of 500,000.
RESULTS: After 8 weeks, the trial-based analysis showed that
with olmesartan versus losartan, valsartan, and irbesartan a
statistically signiﬁcant larger decrease in blood pressure was
achieved (11.5 versus 8.2, 7.9, and 9.9 mmHg [p < 0.05],
respectively). Furthermore, olmesartan resulted in most compli-
cations averted. Cost-effectiveness for olmesartan, losartan, val-
sartan, and irbesartan was estimated at €39,100, €77,100,
€70,700, and €50,900 per cardiovascular complication averted,
respectively. Pharmacy data showed that trial-dosing at 1
‘Deﬁned Daily Dose’ (DDD) was not found in practice. On
average, losartan, valsartan and irbesartan were consequently
dosed above 1 DDD varying from 1.19 to 1.38 ‘Prescribed
Daily Dose’ (PDD), whereas olmesartan was dosed at 0.88
PDD and thus presenting (relatively) lower costs. CONCLU-
SION: Olmesartan was estimated to be the most cost-effective
option of the four ARBs. However, due to differences found in
within-trial versus daily practice dosing and absence of effec-
tiveness data from daily practice, conﬁrmation is needed from
further prospective studies comparing ARBs based on compa-
rable blood pressure control including hard endpoints.
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OBJECTIVES: Despite considerable improvements in the treat-
ment of ST-elevated myocardial infarction (STEMI), patients
remain at long-term risk of additional cardiovascular (CV) events
(such as MI, stroke or vascular death). Over a four week treat-
ment period, the CLARITY-TIMI 28 and COMMIT/CCS-2 trials
demonstrated that clopidogrel (with and without loading dose,
respectively), administered in addition to standard therapy,
reduces the rate of mortality, infarct-related artery patency or MI
(RR 0.64 95% CI 0.53–0.76) and death, reinfarction or stroke
(0.91; 0.86–0.97), respectively. The aim of this study was to
assess the incremental cost per QALY (ICQ) of clopidogrel for
either one month or one year, in addition to standard care in
STEMI patients, from a UK perspective. METHODS: A cohort
Markov model described the experience of new CV events (MI
and stroke) prior to death in patients diagnosed with STEMI. UK
relevant STEMI baseline event rates were synthesised using data
from the literature and observational databases. Event rates in
clopidogrel patients were estimated by applying the aggregate
RRs from the respective trials to the baseline event rates. Health
state costs were derived from relevant UK-based costing studies
and updated to 2006 values, utility values were derived from the
broader literature. Costs and QALYs were discounted at 3.5%, a
full range of deterministic and probabilistic sensitivity analyses
were undertaken. RESULTS: For the 1-month and 1-year treat-
ment options both trials have mean ICQs below 2,500 and
4,000, respectively. In univariate sensitivity analyses the ICQ
never rose above 10,000. The probabilistic sensitivity analysis
showed that in all four analyses, clopidogrel was over 95% likely
to be cost-effective at a QALY value of 20,000. CONCLU-
SION: The estimated ICQs for both treatment options and for
both trials suggest that clopidogrel plus standard therapy is a
cost-effective alternative to standard therapy alone based on
current willingness to pay thresholds.
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OBJECTIVES: Ambulatory hypertension treatment is effective in
reducing mortality and morbidity due to cardiovascular diseases.
There are published evidences of under treatment of hyperten-
sion instead of the existing choice among lots of antihypertensive
medicines. This study aims to explore the antihypertensive medi-
cines prescribing and cost of hypertension therapy in Bulgaria
from the outpatient practice perspective. METHODS: A repre-
sentative sample of 2105 reimbursable prescriptions was col-
lected on a retrospective basis within one year. The prescriptions
were systematized according to the complexity of the therapy
(mono-, di-, three), INN, frequency of the prescribed brand
names of medicines, reimbursement drug prices, as well as,
patient co-payment. To calculate the cost of the outpatient
therapy was build the decision tree model. It matches the differ-
ences in the frequency of particular brand names prescribing and
their prices, as well as the cost dependence on complexity of the
therapy. RESULTS: The ACE inhibitors are the ﬁrst treatment
choice (41%, CI 95%) in the prescriptions, following by beta
blockers 19.43% and calcium channel blockers with 15.2%
share. The prescriptions with one medicine are 61%, di therapy
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